Valuation: Tsubota Laboratory Incorporated

Market Cap 6.68B 42.02M 36.96M 34.84M 31.79M 59.45M 4.03B 59.92M 418M 162M 2.05B 158M 154M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 5.78B 36.36M 31.98M 30.15M 27.5M 51.43M 3.49B 51.84M 362M 140M 1.78B 136M 134M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
08-11 Tsubota Laboratory Incorporated Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06-16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
25-05-11 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
25-02-17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
24-11-20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
22-12-18 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
22-09-19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
1 week-1.89%
Current month-13.09%
1 month-7.17%
3 months+16.67%
6 months-26.42%
Current year-23.82%
1 week 255
Extreme 255
264
1 month 251
Extreme 251
305
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 2019-01-31
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 2024-12-31
Director TitleAgeSince
Director/Board Member 71 2019-01-31
Director/Board Member 70 2020-05-31
Director/Board Member 55 2023-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
11/15/24 Others

Founder

63,000 0.2465%
11/15/24 Others

Founder

420,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-1.89%-26.42%-50.29% 42.02M
+1.46%+4.59%+8.65%+33.71% 48.01B
+2.67%+2.07%+51.74%+38.37% 45.27B
-1.38%+1.84%+9.13%+88.88% 40.93B
+4.78%+1.48%+359.03%+566.20% 42.84B
-0.62%-1.61%+5.30%+46.02% 29.6B
+0.56%+0.88%+24.79%+155.71% 17.32B
+2.05%+1.09%+25.56%+41.67% 15.34B
+3.39%-3.49% - - 15.15B
+7.38%+2.34%+3.80% - 14.84B
Average +2.03%+0.88%+51.29%+115.04% 26.93B
Weighted average by Cap. +1.94%+1.56%+76.89%+150.17%

Financials

2025 2026
Net sales 1.36B 8.54M 7.51M 7.08M 6.46M 12.08M 819M 12.17M 84.93M 32.91M 417M 32.05M 31.35M 200M 1.26M 1.11M 1.04M 952K 1.78M 121M 1.79M 12.52M 4.85M 61.46M 4.72M 4.62M
Net income 205M 1.29M 1.13M 1.07M 976K 1.82M 124M 1.84M 12.83M 4.97M 63M 4.84M 4.74M -761M -4.79M -4.21M -3.97M -3.62M -6.77M -459M -6.83M -47.63M -18.46M -234M -17.97M -17.58M
Net Debt -1.45B -9.11M -8.01M -7.55M -6.89M -12.89M -874M -12.99M -90.63M -35.12M -445M -34.2M -33.46M -901M -5.67M -4.99M -4.7M -4.29M -8.02M -544M -8.08M -56.39M -21.85M -277M -21.28M -20.82M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
26-09-25 JP¥259.00 0.00% 11,600
26-09-24 JP¥259.00 -1.89% 25,600
26-09-18 JP¥264.00 +1.54% 15,000
26-09-17 JP¥260.00 +1.56% 24,100
26-09-16 JP¥256.00 -4.48% 59,300
  1. Stock Market
  2. Stocks
  3. 4890 Stock